# KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

> **NCT04640532** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Kartos Therapeutics, Inc.** · enrollment: 116 (estimated)

## Conditions studied

- Myelofibrosis
- Post-PV MF
- Post-ET Myelofibrosis
- Primary Myelofibrosis

## Interventions

- **DRUG:** KRT-232
- **DRUG:** TL-895

## Key facts

- **NCT ID:** NCT04640532
- **Lead sponsor:** Kartos Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-17
- **Primary completion:** 2022-05-11
- **Final completion:** 2025-07-24
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2022-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640532, "KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04640532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*